Bernard De Prijck

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13

Distinct Clonal Origin in Two Cases of Hodgkin’s Lymphoma Variant of Richter’s Syndrome Associated With EBV Infection

Laurence de Leval, M Vivario, Bernard De Prijck et al. · The American Journal of Surgical Pathology · 2004 · 84 citations

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis et al. · The Lancet Haematology · 2022 · 44 citations

Hematological Malignancy, Oncology, Transplantation +8

Darbepoetin‐alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: A prospective multicenter randomized trial

Yves Béguin, Johan Maertens, Bernard De Prijck et al. · American Journal of Hematology · 2013 · 36 citations · Full text

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial

Kathleen M. Mullane, Vicki A. Morrison, Luis H. Camacho et al. · The Lancet Infectious Diseases · 2019 · 35 citations

Vaccination, Vaccine Safety, Vaccine Development +6